Finishing AP Computer Science Principles is a major milestone, but the leap from block-based coding to real-world JavaScript can feel daunting. Fortunately, the landscape has evolved: Code.org has ...

Diagnosing ATTR-CM early allows clinicians to initiate treatment before substantial amyloid deposits accumulate in the myocardium. The lack of specificity in the clinical presentation of transthyretin ...

Kevin M. Alexander, MD, reflects on ACC data for ATTR-CM and its implications for patient care, stressing that clinical trials and extension analyses show ATTR therapies extend survival, improve ...

In ATTR amyloidosis, a buildup of harmful proteins causes damage to tissues and organs throughout the body, including the heart. Over time, the condition can progress from stage 1, which may cause ...

Advanced disease progression occurred less often with vutrisiran than placebo in both the overall population (8.0% vs 10.7%) and monotherapy subgroup (8.2% vs 11.1%). Transition to NYHA class IV was ...

Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier ...

His voice is easily among the most recognizable in the world. Award-winning actor Morgan Freeman has a presence that can command a room without stepping into it. On and off screen, his steady baritone ...

Learn how TTR stabilizers and gene silencers curb amyloid buildup in ATTR-CM, with trial evidence for fewer hospitalizations and better survival. In ‘Evaluating Transthyretin Stabilizers and Silencers ...

Life expectancy for people with ATTR amyloidosis varies, generally ranging from 3 to 15 years after symptoms appear, and depends on the specific type of the condition and any other health issues a ...

First long-acting therapy with three-monthly dosing to target root cause of cardiac disease The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending ...

Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...